PRINCIPIA BIOPHARMA
Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.
PRINCIPIA BIOPHARMA
Industry:
Biopharma Biotechnology Life Science
Founded:
2008-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.principiabio.com
Total Employee:
11+
Status:
Closed
Contact:
(650) 416-7700
Email Addresses:
[email protected]
Total Funding:
127.8 M USD
Technology used in webpage:
SPF Apache Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Apache 2.4 Amazon SSL Gravity Forms Mimecast
Similar Organizations
Algaeon
Algaeon supplies high-value products derived from algae to companies in the human nutraceutical and fish feed industries.
Artizan Biosciences
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Echo
Echo is a provider of an automated microscope intended for biological research and pathologies.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
FoxBio
FoxBio is a Company that will develop Antoxereneโs collection of small molecules that target senescent cells.
Olipass
OliPass Corporation is committed to revolutionize our views of life sciences and bring us great quality of life.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Mission BioCapital
Mission BioCapital investment in Venture Round - Principia Biopharma
SR One
SR One investment in Series B - Principia Biopharma
Sofinnova Investments
Sofinnova Investments investment in Series B - Principia Biopharma
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series B - Principia Biopharma
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - Principia Biopharma
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Principia Biopharma
OrbiMed
OrbiMed investment in Series B - Principia Biopharma
SR One
SR One investment in Series B - Principia Biopharma
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - Principia Biopharma
Sofinnova Investments
Sofinnova Investments investment in Series B - Principia Biopharma
More informations about "Principia Biopharma"
Sanofi to Acquire Principia for Autoimmune R&D | Sanofi
Aug 17, 2005 Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 908 205 2572 [email protected] Nicolas Kressmann Tel: +1 732 532 5318 โฆSee details»
Principia Biopharma - Crunchbase Company Profile
Oct 30, 2012 Organization. Principia Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Principia Biopharma is dedicated to bringing oral therapies to patients โฆSee details»
Sanofi completes Principia Biopharma Inc. acquisition
Sep 28, 2013 Sanofi completes Principia Biopharma Inc. acquisition *Principia Biopharma Inc. is now a wholly owned subsidiary of Sanofi. PARIS โ September 28, 2020 โ Sanofi announced โฆSee details»
Principia Biopharma - LinkedIn
Principia Biopharma Biotechnology South San Francisco, California 4,741 followers Bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases.See details»
Principia Biopharma - Overview, News & Similar companies
Nov 23, 2020 www.principiabio.com. Revenue <$5 Million. Stock Symbol PRNB. Industry Pharmaceuticals Healthcare . Recent News & Media. Patient Enrollment Concluded Early in โฆSee details»
Principia Biopharma Company Overview, Contact โฆ
Oct 16, 2019 [email protected]: 48%. [email protected]: [email protected]: 2%. See more formats. Frequently Asked Questions Where is Principia Biopharma 's headquarters located? Principia Biopharma 's โฆSee details»
Principia Biopharma - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Principia Biopharma. Use the PitchBook Platform to explore the full profile.See details»
Sanofi to commence tender offer for acquisition of Principia โฆ
Aug 28, 2005 Sanofi has announced that SAR442168 has entered Phase 3 clinical trials in multiple sclerosis. PRN473 Topical, a topical reversible covalent BTK inhibitor designed for โฆSee details»
Principia BioPharma - Craft
Principia BioPharma $35.16 m in annual revenue in FY 2019. See insights on Principia BioPharma including office locations, competitors, revenue, financials, executives, subsidiaries โฆSee details»
Principia Biopharma Inc: Overview - GlobalData
Website www.principiabio.com Telephone 1 650 4167700. Industry Pharmaceuticals and Healthcare. Revenue (2019) $5.2M. Gain access to our premium ...See details»
Sanofi goes all in on Principia, paying $3.7B to take full โฆ
Aug 17, 2020 Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple ...See details»
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Aug 17, 2020 Dive Brief: Sanofi on Monday said it will pay $3.68 billion to acquire partner Principia Biopharma in a deal that gives the French drugmaker full control over a promising โฆSee details»
Sanofi to acquire Principia Biopharma - Nasdaq
Aug 17, 2020 Sanofi to acquire Principia Biopharma. Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor โฆSee details»
Principia Biopharma | Insights
Nov 7, 2024 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
IR call on the acquisition of Principia Biopharma Inc. - Sanofi
Jan 22, 2018 Forward looking statements This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may โฆSee details»
Principia Announces First Patient Dosed in Phase 2A Trial
Sep 17, 2020 For more information, please visit www.principiabio.com. Forward-Looking Statements. This press release contains forward-looking statements. Forward-looking โฆSee details»
Principia Announces Positive Data from its Phase 2 Part B
Jun 12, 2020 Clear dose-response combined with decreased daily corticosteroid usage. Response rate increased with extended duration of treatment to six months while maintaining โฆSee details»
Sanofi to acquire Principia Biopharma - GlobeNewswire
Aug 17, 2020 Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 908 205 2572 [email protected] Nicolas Kressmann Tel: +1 732 532 5318 โฆSee details»
Principia Biopharma, Inc. (Principia Biopharma, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, โฆSee details»
A Leading Immunology Healthcare Company | Sanofi
Nov 13, 2024 Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a โฆSee details»